Immunotoxicotherapy: successes, disappointments and hopes.
Bismuth
C
C
INSERM U26, Hôpital Fernand Widal, Université Paris, France.
Borron
S W
SW
Baud
F J
FJ
Taboulet
P
P
Scherrmann
J M
JM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000506:poisoning; D000997:Antivenins / Q000276:immunology / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000628:therapy; D001666:Binding Sites, Antibody; D003078:Colchicine / Q000276:immunology / Q000506:poisoning; D004077:Digoxin / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000191:economics; D008070:Lipopolysaccharides / Q000009:adverse effects / Q000276:immunology; D011041:Poisoning / Q000628:therapy; D018805:Sepsis / Q000139:chemically induced / Q000628:therapy; D014688:Venoms / Q000009:adverse effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D000929:Antidepressive Agents, Tricyclic; D000997:Antivenins; D007140:Immunoglobulin Fab Fragments; D008070:Lipopolysaccharides; D014688:Venoms; D004077:Digoxin; D003078:Colchicine